Etrolizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Etrolizumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from rat)
Target integrin α7β7
Clinical data
Legal status
?
Identifiers
CAS number 1044758-60-2 N
ATC code None
UNII I2A72G2V3J YesY
Chemical data
Formula C6396H9874N1702O2010S42 
Mol. mass 144.1 kDa
 N (what is this?)  (verify)

Etrolizumab is a humanized monoclonal antibody designed for the treatment of inflammatory bowel disease.[1]

Etrolizumab was developed by Genentech.

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Etrolizumab". American Medical Association.